| scholarly article | Q13442814 |
| P50 | author | Raoul Herbrecht | Q37841047 |
| P2093 | author name string | M Schuster | |
| K A Marr | |||
| J R Wingard | |||
| G Schiller | |||
| S G Revankar | |||
| R J Kryscio | |||
| G Corcoran | |||
| A Langston | |||
| J-A H van Burik | |||
| R N Greenberg | |||
| I Raad | |||
| R Hare | |||
| C E Gonzalez | |||
| M J Abzug | |||
| K Mullane | |||
| G Anstead | |||
| P2860 | cites work | Zygomycetes in human disease | Q24514527 |
| Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P | Q24535844 | ||
| Pulmonary mucormycosis: the last 30 years | Q33674125 | ||
| Rhinocerebral mucormycosis in patients with burns: case report and review of the literature. | Q33698980 | ||
| Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis | Q33716475 | ||
| Infections in patients with diabetes mellitus | Q33796634 | ||
| Disseminated zygomycosis due to Rhizopus schipperae after heatstroke | Q33962099 | ||
| Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. | Q34169909 | ||
| Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. | Q34372568 | ||
| Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 | ||
| Fatal rhino-orbito-cerebral mucormycosis in an apparently normal host: case report and literature review | Q34421375 | ||
| Epidemiology and outcome of zygomycosis: a review of 929 reported cases | Q34440240 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Zygomycosis | Q35038464 | ||
| A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. | Q35179541 | ||
| Voriconazole | Q35179545 | ||
| Infections due to emerging and uncommon medically important fungal pathogens | Q35641420 | ||
| Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men | Q36489989 | ||
| Activity of posaconazole in treatment of experimental disseminated zygomycosis. | Q36880761 | ||
| In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes | Q39651554 | ||
| In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model | Q39652289 | ||
| Eradication of Invasive Mucormycosis--Effectiveness of the Echinocandin FK463 | Q40559190 | ||
| Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients | Q40612999 | ||
| Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). | Q40644002 | ||
| Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor | Q43613091 | ||
| Ten years' experience in zygomycosis at a tertiary care centre in India | Q43729984 | ||
| Abdominal wall mucormycosis successfully treated with amphotericin and itraconazole | Q44051425 | ||
| Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. | Q44073053 | ||
| Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. | Q44134070 | ||
| In vitro susceptibilities of zygomycetes to conventional and new antifungals | Q44257265 | ||
| Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections | Q44417870 | ||
| Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease | Q44575785 | ||
| Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants | Q44777583 | ||
| Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis | Q44818786 | ||
| Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis | Q44839956 | ||
| Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis | Q45018397 | ||
| Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. | Q45051224 | ||
| Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach | Q48277897 | ||
| Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. | Q51190403 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Mucormycosis in hematologic malignancies: an emerging fungal infection | Q73062452 | ||
| Zygomycosis in the 1990s in a tertiary-care cancer center | Q73893355 | ||
| Hyperbaric oxygen as an adjunctive treatment for zygomycosis | Q81870364 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | zygomycosis | Q3046374 |
| P304 | page(s) | 126-133 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Posaconazole as salvage therapy for zygomycosis | |
| P478 | volume | 50 |
| Q38174069 | "We are what we eat!" Invasive intestinal mucormycosis: A case report and review of the literature |
| Q40016281 | A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). |
| Q36290698 | A review of clinical experience with newer antifungals in children |
| Q33285897 | Absidia Corymbifera in an immune competent accident victim with multiple abdominal injuries: case report |
| Q46067606 | Amphotericin and posaconazole for gastrointestinal mucormycosis |
| Q64922614 | Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. |
| Q36589297 | Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q35668229 | Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales |
| Q33962824 | Antifungal susceptibility profile of human-pathogenic species of Lichtheimia |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q40435009 | Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis |
| Q39067518 | Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century |
| Q38866474 | Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options |
| Q46486802 | Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation |
| Q45958411 | Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin. |
| Q57779800 | Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy |
| Q37041199 | CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). |
| Q35784447 | Carbon assimilation profiles as a tool for identification of zygomycetes |
| Q37334159 | Central nervous system infections in immunocompromised patients: update on diagnostics and therapy |
| Q33514740 | Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): a taxonomic update and review of the literature. |
| Q36920608 | Changing epidemiology of rare mould infections: implications for therapy |
| Q37704243 | Chapter 7: zygomycosis |
| Q34708588 | Combat-Related Invasive Fungal Wound Infections |
| Q40185400 | Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient |
| Q81706307 | Combination of umbilical cord blood with BM from a 2-month-old sibling as lifesaving BMT for very severe aplastic anemia |
| Q37636223 | Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. |
| Q38479896 | Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. |
| Q39121097 | Concurrent pulmonary Aspergillus fumigatus and mucor infection in a cardiac transplant recipient: a case report |
| Q38284463 | Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q33826450 | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice |
| Q41850557 | Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection |
| Q82680562 | Cranial epidural abscess and subdural empyema |
| Q37597562 | Current experience in treating invasive zygomycosis with posaconazole. |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q49510166 | Cutaneous mucormycosis |
| Q55446377 | Cutaneous mucormycosis caused by Rhizopus microsporus in an immunocompetent patient: A case report and review of literature. |
| Q36862446 | Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). |
| Q34622554 | Drug strategies targeting CYP51 in neglected tropical diseases |
| Q33573788 | ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients |
| Q40062960 | Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease |
| Q42095363 | Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice |
| Q79300228 | Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q37327080 | Emerging importance of infections due to zygomycetes in organ transplant recipients |
| Q35595623 | Etest cannot be recommended for in vitro susceptibility testing of mucorales |
| Q94554835 | Etiologies of Proptosis: A review |
| Q38891785 | Evaluation of 30 cases of mucormycosis at a university hospital in Iran. |
| Q38744413 | Fatal Pulmonary Mucormycosis due to Rhizopus homothallicus. |
| Q43223060 | Forty-one recent cases of invasive zygomycosis from a global clinical registry. |
| Q90531492 | Fulminant mucormycosis after a traffic accident: a case report |
| Q62241543 | Fungal infection in solid organ recipients |
| Q38202571 | Fungal infections in cancer patients |
| Q90225865 | Fungal infections in children with haematologic malignancies and stem cell transplant recipients |
| Q36768045 | Fungal infections of the CNS: treatment strategies for the immunocompromised patient |
| Q54249354 | Gastric Mucormycosis in a Liver and Kidney Transplant Recipient: Case Report and Concise Review of Literature. |
| Q91171836 | Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium |
| Q35797637 | How I treat mucormycosis |
| Q35196776 | How should we manage a patient with invasive mucoromycosis who develops life-threatening reaction to amphotericin B? Report of two cases and literature review |
| Q35245238 | Human Fungal Pathogens of Mucorales and Entomophthorales |
| Q42100738 | In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest |
| Q34680661 | In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts |
| Q42096347 | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella |
| Q45238820 | In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. |
| Q42139858 | In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents |
| Q33644747 | Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. |
| Q46768531 | Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes |
| Q36612597 | Invasive fungal infections in acute leukemia |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q58007945 | Invasive intracerebral fungal infection in a leukaemic patient |
| Q26823811 | Invasive mold infections in solid organ transplant recipients |
| Q44590211 | Invasive mycoses and trauma |
| Q90714221 | Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system |
| Q38770830 | Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. |
| Q51760177 | Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. |
| Q28082019 | Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent |
| Q37916824 | Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients |
| Q45807101 | Liposomal amphotericin B and surgery as successful therapy for pulmonary Lichtheimia corymbifera zygomycosis in a pediatric patient with acute promyelocytic leukemia on antifungal prophylaxis with posaconazole |
| Q34680771 | Management of neonatal candidiasis. Neonatal Candidiasis Study Group |
| Q40430617 | Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients |
| Q46090408 | Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients |
| Q38227595 | Mold infections of the central nervous system |
| Q39077404 | Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae |
| Q35364288 | Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009 |
| Q43146575 | Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole |
| Q37671994 | Mucormycosis complications in systemic lupus erythematosus |
| Q47222680 | Mucormycosis in Children: Review and Recommendations for Management. |
| Q85000805 | Mucormycosis in Mato Grosso, Brazil: a case reports, caused by Rhizopus microsporus var. oligosporus and Rhizopus microsporus var. rhizopodiformis |
| Q26860727 | Mucormycosis in a renal transplant recipient: case report and comprehensive review of literature |
| Q37607284 | Mucormycosis in an HIV-infected renal transplant patient: A case report and review of the literature |
| Q37534298 | Mucormycosis in immunochallenged patients |
| Q83509366 | Mucormycosis of the head and neck |
| Q24603297 | Mucormycosis, pseudallescheriasis, and other uncommon mold infections |
| Q37859952 | Mucormycosis: its contemporary face and management strategies. |
| Q36597431 | New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage |
| Q37579222 | New generation azole antifungals in clinical investigation |
| Q43232435 | Non-fatal disseminated mucormycosis in a solid organ transplant |
| Q40223620 | Orbital complications of fungal pan-sinusitis in uncontrolled diabetes |
| Q38211830 | Our 2014 approach to mucormycosis. |
| Q55533416 | Patient With Abdominal Pain-Concealing Gastrointestinal Mucormycosis. |
| Q40243271 | Pearls & Oy-sters: isolated cerebral zygomycosis in an intravenous drug user |
| Q37756116 | Pharmacokinetic/pharmacodynamic profile of posaconazole |
| Q37115829 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers |
| Q26771180 | Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections |
| Q46341880 | Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. |
| Q37247780 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers |
| Q39429649 | Phylogenetic analysis reveals two genotypes of the emerging fungus Mucor indicus, an opportunistic human pathogen in immunocompromised patients |
| Q80066469 | Posaconazole |
| Q93480679 | Posaconazole (Noxafil), an Extended-Spectrum Oral Triazole Antifungal Agent |
| Q40452729 | Posaconazole (Noxafil): a new triazole antifungal agent. |
| Q36424973 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| Q38899363 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole |
| Q36718486 | Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature |
| Q43189988 | Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. |
| Q37052755 | Posaconazole in the management of refractory invasive fungal infections |
| Q34498982 | Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases |
| Q42183489 | Posaconazole mono- or combination therapy for treatment of murine zygomycosis |
| Q43756553 | Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. |
| Q43056048 | Posaconazole salvage treatment in paediatric patients: a multicentre survey |
| Q35262607 | Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. |
| Q42798609 | Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes |
| Q37094649 | Posaconazole treatment in Korea: single-center experience over 5 years |
| Q37404840 | Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update |
| Q41848545 | Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections |
| Q36828159 | Posaconazole: a new broad-spectrum antifungal agent |
| Q33382991 | Posaconazole: a new oral antifungal agent with an expanded spectrum of activity |
| Q40188974 | Posaconazole: a next-generation triazole antifungal |
| Q39575509 | Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. |
| Q28291282 | Posaconazole: an oral triazole with an extended spectrum of activity |
| Q37901534 | Posaconazole: when and how? The clinician's view |
| Q40845897 | Primary cutaneous mucormycosis developing after incision and drainage of a subcutaneous abscess in an immunocompetent host |
| Q38950932 | Pulmonary mucormycosis: clinical features and outcomes. |
| Q54222905 | Rare Orbital Infections ~ State of the Art ~ Part II. |
| Q24642450 | Recent advances in the management of mucormycosis: from bench to bedside |
| Q34161213 | Recent advances in the treatment of mucormycosis |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q38341595 | Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole |
| Q37370491 | Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases |
| Q38017577 | Rhino-orbital-cerebral mucormycosis |
| Q37451673 | Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia |
| Q47697145 | Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations. |
| Q26740837 | Role of isavuconazole in the treatment of invasive fungal infections |
| Q43682695 | Siderophore production by pathogenic mucorales and uptake of deferoxamine B. |
| Q92586706 | Skull Base Mucormycosis in an Immunocompetent Patient: A Case Report and Literature Review |
| Q36568458 | Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections |
| Q44494625 | Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia |
| Q79300230 | The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida |
| Q37800610 | The value of amphotericin B in the treatment of invasive fungal infections |
| Q26746016 | Therapeutic Drug Monitoring of Posaconazole: an Update |
| Q90672647 | Therapy of Mucormycosis |
| Q54935900 | Total Gastric Necrosis Due to Mucormycosis: A Rare Case of Gastric Perforation. |
| Q46302490 | Treatment options in emerging mold infections |
| Q36521993 | Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole |
| Q37910256 | Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment |
| Q47127046 | Urinary tract aspergillosis in a patient with chronic kidney disease |
| Q43101266 | Use of posaconazole in the treatment of infective rhinocerebral mucormycosis |
| Q37810083 | Use of posaconazole in the treatment of invasive fungal infections |
| Q38890514 | Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection |
| Q46684813 | Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients |
| Q39296502 | Zygomycosis caused by Rhizopus microsporus and Rhizopus oryzae in Madhya Pradesh (M.P.) Central India: a report of two cases |
| Q35010681 | Zygomycosis in Immunocompromised non-Haematological Patients. |
| Q45945768 | Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). |
| Q46902095 | Zygomycosis: an emerging fungal infection with new options for management |
| Q83392396 | [Antifungal therapy update: new drugs and medical uses] |
Search more.